Q1 2016 13F Holders as of 31 Mar 2016
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
77,331,078
-
Total 13F shares
-
5,691,967
-
Share change
-
-68,125
-
Total reported value
-
$39,789,000
-
Price per share
-
$6.99
-
Number of holders
-
24
-
Value change
-
-$1,434,188
-
Number of buys
-
8
-
Number of sells
-
7
Institutional Holders of Xenon Pharmaceuticals Inc. - Common Stock (XENE) as of Q1 2016
As of 31 Mar 2016,
Xenon Pharmaceuticals Inc. - Common Stock (XENE) was held by
24 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
5,691,967 shares.
The largest 10 holders included
BVF INC/IL, Capital World Investors, ROYAL BANK OF CANADA, Invesco Private Capital, Inc., Visium Asset Management, LP, Opaleye Management Inc., Point72 Asset Management, L.P., PERCEPTIVE ADVISORS LLC, DAFNA Capital Management LLC, and Novo A/S.
This page lists
24
institutional shareholders reporting positions in this security
for the Q1 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.